Your browser doesn't support javascript.
Guillain-Barre syndrome following COVID-19 vaccines: A scoping review.
Lahoz Fernandez, Paulo Eduardo; Miranda Pereira, Jorge; Fonseca Risso, Isabela; Baleeiro Rodrigues Silva, Paula; Freitas Barboza, Ingrid Caroline; Vieira Silveira, Coralia Gabrielle; Diogo Silva, Guilherme; Marzorati Kuntz Puglia, Paula; Genaro Mutarelli, Eduardo.
  • Lahoz Fernandez PE; Department of Neurology, Syrian Lebanese Hospital, São Paulo, Brazil.
  • Miranda Pereira J; Department of Neurology, Syrian Lebanese Hospital, São Paulo, Brazil.
  • Fonseca Risso I; Department of Neurology, Syrian Lebanese Hospital, São Paulo, Brazil.
  • Baleeiro Rodrigues Silva P; Department of Neurology, Syrian Lebanese Hospital, São Paulo, Brazil.
  • Freitas Barboza IC; Department of Neurology, Syrian Lebanese Hospital, São Paulo, Brazil.
  • Vieira Silveira CG; Department of Neurology, Federal University of São Paulo, São Paulo, Brazil.
  • Diogo Silva G; Department of Neurology, Syrian Lebanese Hospital, São Paulo, Brazil.
  • Marzorati Kuntz Puglia P; Department of Neurology, State Civil Servant Hospital of São Paulo, São Paulo, Brazil.
  • Genaro Mutarelli E; Department of Neurology, Syrian Lebanese Hospital, São Paulo, Brazil.
Acta Neurol Scand ; 145(4): 393-398, 2022 Apr.
Article in English | MEDLINE | ID: covidwho-1583695
ABSTRACT
Guillain-Barre syndrome following COVID-19 vaccines (GBSfCV19v) is a reported adverse effect that remains unclear. We present a structured review based on two case reports of GBSfCV19v, a systematic review, and Vaccine Adverse Event Reporting System (VAERS) analysis to estimate the risk and describe the clinical characteristics (CC) of these events. We've searched on MEDLINE and Embase, from the inception to May 20, 2021, using the keywords "Guillain barre syndrome" and cross-referenced with "covid-19 vaccines." We estimated the risk of GBSfCV19v, comparing it with the risk of GBS following the influenza vaccine (GBSfIv), considering the VAERS sensitivity. The clinical characteristics included age, sex, comorbidities, type of vaccine, administered dose, clinical onset, deaths, cerebrospinal fluid (CSF), and electromyography (EMG) pattern. We found 43 cases, considering the risk of GBSfCV19v lower than GBSfIv (160-320 cases). The patients had a mean age of 54 years and 23 (56%) were male. The types of vaccines used Pfizer (22), Moderna (9), AstraZeneca (3), Janssen (3), and Johnson & Johnson (1). 24 cases of GBS occurred after the first dose, with clinical onset of 7 days. CSF albuminocytological dissociation was reported in 7 patients, and EMG revealed a predominant demyelinating pattern. GBSfCV19v risk appears to be lower than what was expected from other respiratory virus vaccines. Most cases of GBS were middle-aged males within a week following the first dose of the COVID-19 vaccine, showing a typical demyelinating neuropathy with albuminocytological dissociation.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Influenza Vaccines / Guillain-Barre Syndrome / COVID-19 Type of study: Case report / Observational study / Prognostic study / Randomized controlled trials / Reviews / Systematic review/Meta Analysis Topics: Vaccines Limits: Humans / Male / Middle aged Language: English Journal: Acta Neurol Scand Year: 2022 Document Type: Article Affiliation country: Ane.13575

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Influenza Vaccines / Guillain-Barre Syndrome / COVID-19 Type of study: Case report / Observational study / Prognostic study / Randomized controlled trials / Reviews / Systematic review/Meta Analysis Topics: Vaccines Limits: Humans / Male / Middle aged Language: English Journal: Acta Neurol Scand Year: 2022 Document Type: Article Affiliation country: Ane.13575